DexCom, Inc. vs Financial Select Sector SPDR Fund — how do they compare? DexCom, Inc. trades at $77.79 (market cap $28.06B), while Financial Select Sector SPDR Fund trades at $56.76. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | XLF | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $56.56 |
52-Week Low | $54.84 | $47.80 |
Enterprise Value | $27.03B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
XLF trades at $56.63, up 0.8% on the day, with strong technical momentum indicated by bullish moving averages and ADX readings. The ETF is poised ahead of Q2 bank earnings, with expectations for strong results driven by trading activity and loan demand. Recent Federal Reserve stress tests have enabled dividend increases, including XLF's upcoming $0.19 distribution.
The outlook for XLF is positive, supported by potential Federal Reserve rate hikes that typically benefit financial stocks. Key risks include geopolitical tensions from the Iran conflict and any earnings disappointments from major bank components. Investor sentiment is optimistic, focusing on earnings catalysts and sector rotation opportunities.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →